Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria

El-Samahy, Mona H.; Elhenawy, Yasmine Ibrahim; Nawar, Marwa Magdy

doi:10.1016/j.jdiacomp.2015.02.008

Cited by 7 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, we noted a significant correlation with plasma OPG levels and microalbuminuria which may support the concept that elevated plasma OPG may be associated with diabetic nephropathy. These findings are in agreement with previous studies . It has been demonstrated that patients with nephropathy and high OPG levels had significantly higher all‐cause mortality than patients with low levels (Table ).…”

Section: Discussionsupporting

confidence: 93%

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Fekih

Triki

et al. 2016

Pediatr Diabetes

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Fekih

Triki

et al. 2016

Pediatr Diabetes

View full text Add to dashboard Cite

show abstract

“…Given the inconsistent results of previous studies, we performed subgroup analyses to identify the effects of the serum OPG level on renal prognosis. We divided patients into subgroups based on factors associated with the serum OPG level: old age [43], presence of diabe- tes mellitus [43,44], and decreased eGFR [33][34][35]. Notably serum OPG level showed a statistically significant link with renal prognosis in all subgroups.…”

Section: Discussionmentioning

confidence: 99%

Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study)

Myeong

Song

et al. 2022

Kidney Res Clin Pract

View full text Add to dashboard Cite

Background: Osteoprotegerin is an important regulator of bone metabolism and vascular calcification. The association between serum osteoprotegerin level and chronic kidney disease (CKD) progression has not been elucidated. We investigated the prognostic value of serum osteoprotegerin levels in nondialysis CKD patients. Methods: We analyzed 2,082 patients enrolled in the Korean Cohort Study for Outcomes in Patients with CKD between 2011 and 2016. Patients were divided into quartiles by their serum osteoprotegerin levels. The primary outcome was the occurrence of ≥1 of the following: dialysis initiation, kidney transplantation, a two-fold increase in serum creatinine level from baseline, or a 50% decrease in the estimated glomerular filtration rate (eGFR). Cox proportional hazard regression models were used to investigate the prognostic value of the serum osteoprotegerin level to CKD progression. Results: The median follow-up period was 48.9 months, and 641 patients (30.8%) experienced the primary outcome. The hazard ratio of serum osteoprotegerin for renal progression in the full extended Cox proportional hazard model was 1.064 (95% confidence interval, 1.041-1.088). Subgroup analyses by age, presence of diabetes, and eGFR showed significant results consistent with the overall analysis results. Conclusion: Serum osteoprotegerin level is independently associated with renal prognosis and could have prognostic importance in CKD progression.

show abstract

“…In particular, miR-23~27~24 clusters positively correlated with OPG, also known as TNF receptor superfamily, member 11b, a member of the TNFrelated family implicated in the process of bone remodelling [50][51][52]. Importantly, OPG is involved in the pathogenesis of a plethora of diabetic complications: retinopathy; angiopathy; low bone mineral density with lower osteoblast and increased osteoclast signalling, predisposing to adult osteopenia and osteoporosis; extraosseous calcification, resulting in stiffening of the arteries and subsequent vascular insufficiency; nephropathy; and general cardiovascular morbidity in children with type 1 diabetes [53][54][55][56][57][58][59][60].…”

Section: Discussionmentioning

confidence: 99%

Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis We aimed to analyse the association between plasma circulating microRNAs (miRNAs) and the immunometabolic profile in children with type 1 diabetes and to identify a composite signature of miRNAs/immunometabolic factors able to predict type 1 diabetes progression. Methods Plasma samples were obtained from children at diagnosis of type 1 diabetes (n = 88) and at 12 (n = 32) and 24 (n = 30) months after disease onset and from healthy control children with similar sex and age distribution (n = 47). We quantified 60 robustly expressed plasma circulating miRNAs by quantitative RT-PCR and nine plasma immunometabolic factors with a recognised role at the interface of metabolic and immune alterations in type 1 diabetes. Based on fasting C-peptide loss over time, children with type 1 diabetes were stratified into the following groups: those who had lost >90% of C-peptide compared with diagnosis level; those who had lost <10% of C-peptide; those showing an intermediate C-peptide loss. To evaluate the modulation of plasma circulating miRNAs during the course of type 1 diabetes, logistic regression models were implemented and the correlation between miRNAs and immunometabolic factors was also assessed. Results were then validated in an independent cohort of children with recent-onset type 1 diabetes (n = 18). The prognostic value of the identified plasma signature was tested by a neural network-based model. Results Plasma circulating miR-23~27~24 clusters (miR-23a-3p, miR-23b-3p, miR-24-3p, miR-27a-3p and miR-27b-3p) were upmodulated upon type 1 diabetes progression, showed positive correlation with osteoprotegerin (OPG) and were negatively correlated with soluble CD40 ligand, resistin, myeloperoxidase and soluble TNF receptor in children with type 1 diabetes but not Electronic supplementary material The online version of this article (

show abstract

Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria

Cited by 7 publications

References 23 publications

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study)

Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes

Contact Info

Product

Resources

About